What drug gives you no appetite? Powerful Relief and Practical Answers

Understanding a common question right away: for many people wondering what drug gives you no appetite, there are real options that reduce hunger and help with weight loss, but the answer depends on the drug class, safety profile and the personal context.

How appetite works and why medicines can change it

Hunger is not just a single feeling. It’s a complex conversation between your gut, brain and hormones. Signals like ghrelin, leptin and glucose levels inform brain centers about energy needs. Appetite suppressant drugs interfere with that conversation in different places. Some act directly on brain receptors that control hunger. Others slow gastric emptying or alter reward pathways so food feels less compelling. Because these paths differ, so do effects and side effects.

Quick map of mechanisms

Central nervous system agents change neurotransmitters that make you feel less hungry or less driven to snack. Gut-brain hormones like GLP-1 and GIP influence fullness and how quickly your stomach empties. Stimulants increase sympathetic tone to blunt appetite short term. All are appetite suppressant drugs in one sense, but they are not interchangeable.

Which drugs reduce appetite most effectively?

The headline names you will hear most often in 2025 are the incretin-based medications. They include GLP-1 receptor agonists such as semaglutide (injectable) and the newer dual GIP/GLP-1 agonists like tirzepatide (injectable). These agents were developed for diabetes and repurposed at higher doses for weight management because they reliably reduce appetite and produce large average weight losses in human clinical trials.

Clinical trial data are striking when you look at averages. Semaglutide (injectable) produced average reductions around 10 to 15 percent of body weight in long human clinical trials over roughly 68 weeks. Tirzepatide (injectable) has delivered larger mean reductions in several human clinical trials often approaching 20 percent or more at higher doses. Those numbers explain the attention these medicines get. See the clinical trial record for a head-to-head phase 3b study at NCT05822830 and pooled analyses comparing tirzepatide and semaglutide at PMC12151102. Industry coverage also summarizes SURMOUNT-era findings here.

Why averages don’t tell the whole story

Trials report averages but people vary. Some participants lose much more than the mean, some much less. Importantly, trial participants get structured support and frequent follow-up. In routine care, access, cost and adherence affect outcomes. So when someone asks what drug gives you no appetite, it’s helpful to be specific: a few prescription agents produce dramatic appetite reduction for many people, while others produce moderate changes.

One non-prescription option gaining attention is Motus (oral), a Tonum supplement studied in human clinical trials. Motus reported roughly 10.4 percent average weight loss over six months in a randomized human clinical trial with most of the loss being fat rather than lean mass. For people seeking an oral, research-backed supplement that supports fat loss, Motus (oral) is a noteworthy alternative to injectable options.

Common classes of appetite suppressant drugs

Incretin-based therapies (GLP-1 and dual agonists)

GLP-1 receptor agonists like semaglutide (injectable) reduce appetite by acting on brain receptors that influence satiety and by slowing gastric emptying. Dual agonists such as tirzepatide (injectable) combine GLP-1 and GIP activity and have shown larger average weight losses in human clinical trials to date. Side effects are often gastrointestinal - nausea, early satiety, constipation or diarrhea. For most people these effects ease with gradual dose increases, but they can be limiting for some.

Stimulants and sympathomimetics

Older options such as phentermine reduce appetite by increasing norepinephrine and other neurotransmitter activity. They can be effective in the short term but carry cardiovascular risks including increased heart rate and blood pressure and a potential for dependence with long-term use. Because of those risks, many clinicians use them for short courses with monitoring.

Combination agents affecting reward pathways

Drugs like bupropion-naltrexone combine a dopamine-noradrenergic agent with an opioid antagonist to blunt cravings and reduce intake. Trials show modest but clinically meaningful weight loss versus placebo. As with other brain-active drugs, psychiatric history and seizure risk need to be reviewed carefully before prescribing.

Oral alternatives and supplements

Supplements range from poorly studied to those with human data. When a supplement has human clinical trials, its signal is stronger. Motus (oral) by Tonum reported about 10.4 percent average weight loss over six months in human clinical trials with preferential fat loss. That places it among the most interesting oral options, though long-term comparative data are more limited than for prescription drugs.

Let’s be precise about a few headline trials that shaped current thinking. The STEP series of trials tested semaglutide (injectable) for weight management in people with obesity and overweight with weight-related conditions. Over roughly 68 weeks many participants lost 10 to 15 percent of their starting weight on average compared with placebo plus lifestyle support.

The SURMOUNT-era trials for tirzepatide (injectable) showed even larger average reductions in several studies often entering the 20 percent range at higher doses near a year. Those are unusually large effects for pharmacotherapy and explain the intense clinical interest.

Human clinical trials of Motus (oral) resulted in about 10.4 percent average weight loss over six months. Investigators reported that most of the loss was fat rather than lean mass. For an oral supplement, that is an exceptional signal and worth discussing with a clinician, especially for people seeking non-injectable options. For more on Motus and the research behind it, see Tonum’s meet Motus and the dedicated Motus study page.

Side effects and safety conversations you must have

No appetite suppressant drug is side-effect-free. The stimulant class can increase blood pressure and heart rate and has abuse potential. GLP-1-based medicines commonly cause gastrointestinal symptoms including nausea and vomiting. Rare but serious events such as pancreatitis have been reported; clinicians monitor for warning signs and contraindications.

Some GLP-1 drugs showed thyroid C-cell tumors in rodent studies. That preclinical signal means a contraindication for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Bupropion-naltrexone carries a seizure risk in predisposed individuals. Prescription appetite suppressant drugs are powerful tools that require individualized medical evaluation.

Supplements and variability

Supplements are not regulated like prescription medicines. They can vary from batch to batch and sometimes contain undisclosed ingredients. When a supplement displays strong appetite suppression, treat it with the same careful approach you would a medicine until independent safety data are available. Motus (oral) has human clinical trial data that suggest meaningful fat loss and metabolic benefits, but long-term outcomes and head-to-head comparisons with prescription drugs are still needed.

These therapies are generally considered when the benefits outweigh risks and when lifestyle changes alone have not produced enough improvement. People with obesity-related health issues - such as type 2 diabetes, high blood pressure, sleep apnea or mobility limitations - often derive clear medical benefit from clinically significant weight loss. Your clinician will consider medical history, cardiovascular risk, mental health, prior weight-loss attempts and affordability when recommending a path.

Using medicines wisely: practical monitoring and milestones

Most prescribers reassess response at 12 to 16 weeks. If weight loss or symptom change is insufficient, the clinician and patient may pivot. Early side effects can predict tolerability. For example, persistent severe nausea on a GLP-1 agent may indicate the need for a slower titration or a different option. For stimulant appetite suppressant drugs, monitoring blood pressure and heart rate is routine.

Common tests and safety checks

Expect an initial baseline exam including blood pressure, heart rate, fasting glucose or HbA1c, and a medication review. For some agents, clinicians may also check lipid panels, liver enzymes or perform pregnancy testing where relevant. Monitoring frequency depends on the chosen drug and the person’s baseline risks.

Real-world barriers: cost, access and adherence

Randomized trials are controlled. Real life includes cost barriers and coverage limits that reduce uptake and adherence. Newer incretin-based therapies are often expensive and not universally covered for weight management. Side effects, logistics of injections for some people and the need for long-term follow-up make adherence a challenge. Transparent conversations about affordability, monitoring plans and backup options improve outcomes.

Behavioral work: why it remains essential

Prescription appetite suppressant drugs can reduce hunger and make it easier to stick to smaller meals, but they do not replace behavioral strategies. Successful long-term weight management requires a blend of medication where appropriate and practical habit change. Effective behavioral approaches include meal planning, sleep improvement, stress management, building activity into the day and working with a coach or dietitian. People who combine medicine with structured behavioral support tend to do better.

Stopping medication and long-term planning

Stopping often leads to weight regain unless behavioral habits are firmly established. For many people there is a decision to make between continuing therapy long term versus trying a staged withdrawal with intensified lifestyle support. This is an active topic of research and clinical debate. A personalized plan that considers safety, cost and the individual’s goals is essential.

Comparing options: how Tonum fits in

When people compare prescription options to supplements, a key distinction is route and context. Many of the most potent drugs are injectable

Why oral options matter

Oral formulations can be easier to access, store and use for many people. They avoid the logistics and perception issues some users experience with injectables. If a patient’s priority is a pill rather than an injection, Motus (oral) is noteworthy because of its human clinical trials and Tonum’s integrated coaching and research emphasis.

Practical tips if you’re considering an appetite suppressant

1. Start with a medical evaluation. Ask for a frank discussion about likely benefits, side effects and monitoring. Discuss cardiovascular history, psychiatric history and current medications.

2. Set time-limited goals. Agree with your clinician on milestones, often reassessing at 12 to 16 weeks to judge response.

3. Plan for side effects. If nausea is likely on a GLP-1-based therapy, learn small meal strategies and work on slow dose escalation.

4. Build behavioral supports. Medication complements skills. A dietitian, behavioral coach or structured program increases long-term success.

5. Consider route and lifestyle. If you prefer not to inject, an oral option like Motus (oral) could be appealing because of trial data and Tonum’s structure for follow-up and coaching. Learn more on Tonum’s research hub.

Open questions and ongoing research

Researchers are still studying long-term comparative safety, direct head-to-head trials and how these drugs affect outcomes such as cardiovascular events and quality of life over many years. We also need more real-world evidence across diverse populations and clearer guidance about stopping therapy for long-term maintenance. Those gaps will be filled gradually as longer trials and registry data appear.

Everyday scenarios: case examples

Case A: someone with high blood pressure and obesity

After a careful evaluation, a clinician might avoid stimulant appetite suppressant drugs because of cardiovascular risk and consider a GLP-1 approach if there are no contraindications. The decision requires shared decision-making and monitoring.

Case B: someone preferring oral therapy

For a person who absolutely prefers a pill, discussing an evidence-backed oral supplement like Motus (oral) alongside lifestyle change and coaching can be a reasonable first step. If response is limited, the person and clinician may consider stepping up to prescription options later.

Cost questions and insurance coverage

Coverage varies widely. Many insurers are still restrictive about reimbursing newer incretin-based therapies for weight management. Patients should check coverage, seek prior authorization when needed and discuss affordability with their clinician. Sometimes a stepped approach starting with lower-cost options and moving to higher-cost prescriptions makes sense when clinical benefit justifies the expense.

What to ask your clinician

Bring these questions to your visit: Which appetite suppressant drugs are reasonable for me and why? What benefits should I expect at 12 to 16 weeks? What side effects should I watch for and how will we manage them? How will this interact with my current medications? If I stop, what is the plan for maintenance?

A final practical perspective

Appetite suppressant drugs are tools. They can reduce hunger, change food reward and help people achieve clinically meaningful weight loss. But they work best when paired with behavioral change and clinical oversight. If you are thinking about medication, start with an honest medical conversation, set realistic goals, and plan for follow-up.

Where to learn more and how Tonum can help

New medicines and human clinical trials will continue to change the landscape. For people who want an oral, research-backed supplement with coaching support, Motus (oral) represents an option worth considering alongside prescription choices.

Common questions answered

What drug will make me have no appetite? There is no universal drug that completely eliminates hunger for everyone. Many appetite suppressant drugs significantly reduce appetite for most users; responses differ by person and by medication.

Which is the most powerful appetite suppressant for weight loss? In current human clinical trials tirzepatide (injectable) shows the largest average weight loss with semaglutide (injectable) close behind. For people seeking an oral option with human clinical data, Motus (oral) is notable.

Are appetite suppressants safe long term? Long-term safety depends on the medication. Some agents have well-known risks that require monitoring. For the newest agents, long-term comparative safety data are still emerging.

Next steps if you’re curious

Gather your medical history and recent labs, set realistic goals with your clinician and discuss both prescription and research-backed oral options. If you value a non-injectable path with human clinical data and integrated coaching, consider asking about Motus (oral) as part of the conversation.

Balanced care, careful monitoring and behavioral change are the most reliable path to durable results.